In this REUP episode, we replay a section of our interview with Dr. Michael Hayes of Kaiser Permanente. This audio was first aired on episode 2.01. The interview is on the relationship between conflict of interest and editorial stance on tumor-treating fields for glioblastoma multiforme.

TTF: doi.org/10.1016/j.jcpo.2019.100189

Back us on Patreon! www.patreon.com/plenarysession

This week we launch a new segment on Plenary Session: Question of the Week! We invite Dr. Sven Olson on to ask a sample hematology/oncology boards question and we invite Audrey Tran on to ask a question from a medical student. Before that, we talk about the legacy of Dr. Charles Moertel and how modern oncologists, in contrast, will be remembered. We end the episode with an interview with Dr. Adam Obley of OHSU -- his fourth appearance on the podcast! -- on cancer screening.

Dr. Moertel's obituary: https://www.nytimes.com/1994/06/29/obituaries/charles-moertel-66-studied-treatment-and-cost-of-cancer.html

Faith Lost, a Doctor Turns Bitter: https://www.latimes.com/archives/la-xpm-1993-09-12-mn-34516-story.html

Not So Silver Lining: doi.org/10.1001/archinternmed.2011.73

Mammography Screening: Truth, Lies and Controversy: https://www.crcpress.com/Mammography-Screening-Truth-Lies-and-Controversy/Gotzsche/p/book/9781846195853

Back us on Patreon! www.patreon.com/plenarysession

This BONUS episode is a recording of a lecture that Dr. Stacie Dusetzina of Vanderbilt University gave for grand rounds at OHSU on June 19, 2019. The lecture is on the cost of prescription drugs and out-of-pocket spending.

Back us on Patreon! www.patreon.com/plenarysession

Welcome to season 2! We're starting this season off with a little bit of everything: a critique of the FDA's accelerated approval of selinexor for penta-refractory multiple myeloma; an interview with Dr. John Reneau of Ohio State University on ECHELON-2 (brentuximab vedotin in t-cell lymphomas); an interview with Dr. Michael Hayes of Kaiser Permanente on parachutes in medicine plus the relationship between conflict of interest and editorial stance on tumor-treating fields for glioblastoma multiforme; and an interview with Dr. Stacie Dusetzina - a leading researcher in health care policy and the cost of cancer drugs, and an avid Twitter user - of Vanderbilt University on #MedTwitter.

ECHELON-2: doi.org/10.1016/S0140-6736(18)32984-2

Facing Our Mistakes: doi.org/10.1056/NEJM198401123100211

Parachutes: doi.org/10.9778/cmajo.20170088

TTF: doi.org/10.1016/j.jcpo.2019.100189

Impact of Disclosing Financial Ties: doi.org/10.1001/archinternmed.2010.39

Back us on Patreon! www.patreon.com/plenarysession

We begin this week's episode by breaking down the recent phase III trial on voxeletor in sickle cell disease with Dr. Sven Olson of OHSU. Next, we feature guest Dr. David Steensma of the Dana-Farber Cancer Institute in a far-reaching interview on being well-read, running a small lab, humanizing cancer, learning from our past use of erythropoiesis-stimulating agents, understanding the headache of contract research organizations, defining cancer, and more!

Voxeletor in Sickle Cell: doi.org/10.1056/NEJMoa1903212

Don't Mention It: doi.org/10.1200/JCO.2008.17.7238

The Raven: doi.org/10.1200/JCO.2017.76.3458

Erythropoietin Use in Cancer: doi.org/10.1200/JCO.2005.05.036

Contract Research Organizations: doi.org/10.1002/cncr.29994

Back us on Patreon! www.patreon.com/plenarysession

This week we begin the episode by discussing MONALEESA-7 and why ribociclib has been shown to increase overall survival while palbociclib has not. We finish the episode with an in-depth interview with Dr. Stacie Dusetzina of Vanderbilt University on her work in pharmacoeconomics, specifically we discuss her work on the market value of cancer drugs.

MONALEESA-7: doi.org/10.1056/NEJMoa1903765

Free drug samples are a marketing tool: doi.org/10.2105/AJPH.2007.114249

Back us on Patreon! www.patreon.com/plenarysession

This week we open with a critical take on our current system of disseminating scientific research, specifically focusing on the prevalence of -- and dependence on -- medical writers. In the second half of the episode, we interview Dr. Allen Pannell of the Haslam College of Business at the University of Tennessee on using a Frequentist approach vs a Bayesian approach in the context of a single clinical trial.

Frequentist vs Bayesian: doi.org/10.1136/bmjopen-2018-024256

Dr. Pannell's breast cancer support group: https://www.breastconnect.org/

Dr. Pannell's research project: http://tinyurl.com/peerErPrHer2

Back us on Patreon! www.patreon.com/plenarysession

In this BONUS episode we give advice on how to use Twitter effectively: how to focus your content, how to build your Twitter following, and how to conceptualize of the platform as an information network.

Back us on Patreon! www.patreon.com/plenarysession

This week we discuss the recent paper "Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?" with its author, Dr. Joaquín Chapa of OHSU. We then revisit the POLO trial with Dr. Emerson Chen of OHSU, who disagrees with last episode's analysis.

Effectiveness of Screening: doi.org/10.1016/j.mayocp.2019.02.016

POLO: doi.org/10.1056/NEJMoa1903387

Back us on Patreon! www.patreon.com/plenarysession

This week we cover some of the highlights from this year's ASCO annual meeting. We discuss the POLO study "Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer" and the TITAN study "Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer", both recently published in NEJM. We end with a presentation titled "Expedited Program Use and Patient Experience in Trials", which was given in a shortened version at ASCO.

POLO: doi.org/10.1056/NEJMoa1903387

TITAN: doi.org/10.1056/NEJMoa1903307

Back us on Patreon! www.patreon.com/plenarysession